These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 38025915)

  • 1. Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan.
    Marumo Y; Yoshida T; Furukawa Y; Ina K; Kamiya A; Kataoka T; Kayukawa S
    Clin Exp Vaccine Res; 2023 Oct; 12(4):319-327. PubMed ID: 38025915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies.
    Heftdal LD; Hamm SR; Pérez-Alós L; Madsen JR; Armenteros JJA; Fogh K; Kronborg CC; Vallentin AP; Hasselbalch RB; Møller DL; Hansen CB; Pries-Heje M; Gang AO; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Iversen K; Garred P; Nielsen SD; Grønbaek K
    Eur J Haematol; 2023 Aug; 111(2):229-239. PubMed ID: 37151174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
    Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
    Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study "Cervax".
    Mohamed S; Lucchini E; Sirianni F; Porrazzo M; Ballotta L; Ballerini M; De Sabbata GM; De Bellis E; Cappuccio I; Granzotto M; Toffoletto B; Fortunati I; Russignan A; Florea EE; Torelli L; Zaja F
    Front Oncol; 2023; 13():1133348. PubMed ID: 36923438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.
    Perry C; Luttwak E; Balaban R; Shefer G; Morales MM; Aharon A; Tabib Y; Cohen YC; Benyamini N; Beyar-Katz O; Neaman M; Vitkon R; Keren-Khadmy N; Levin M; Herishanu Y; Avivi I
    Blood Adv; 2021 Aug; 5(16):3053-3061. PubMed ID: 34387648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors predictive of anti-spike antibody titers after COVID-19 vaccination in hemodialysis patients.
    Aoun M; Kahwaji RM; Sleilaty G; Boueri C; Hawi J; Khalil CB; Hage V
    Adv Clin Exp Med; 2022 Aug; 31(8):855-861. PubMed ID: 35438849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
    Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [SARS-CoV2 anti-spike IgG response following COVID-19 mRNA vaccination (BNT162b2) in patients with hematological disorders].
    Hagihara M; Sugi T; Uchida T; Ohara S; Imai Y; Inoue M; Mitamura K
    Rinsho Ketsueki; 2022; 63(4):247-253. PubMed ID: 35491212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between a low response to rubella vaccination and reduced anti-severe acute respiratory syndrome coronavirus 2 immune response after vaccination with BNT162b2: a cross-sectional study.
    Nakaharai K; Nakazawa Y; Mishima Y; Saito M; Shinozaki Y; Yoshida M
    Clin Microbiol Infect; 2023 Feb; 29(2):253.e1-253.e5. PubMed ID: 36150670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study.
    Sugihara K; Wakiya R; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Ushio Y; Mizusaki M; Mino R; Chujo K; Nomura Y; Inoo M; Kadowaki N; Dobashi H
    Medicine (Baltimore); 2022 Oct; 101(42):e31288. PubMed ID: 36281134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.
    Pascale SP; Nuccorini R; Pierri T; Di Mare R; Fabio L; Lerose E; Merlino MA; Schiavo P; Amendola A; Brucoli G; Caputo MD; Chitarrelli I; Cimminiello M; Coluzzi S; Filardi NB; Matturro A; Vertone D; Poggiaspalla M; Malaspina F; Musuraca G; Coralluzzo G; Mannarella C; Musto C; Bellettieri AP; Martinelli G; Cerchione C; Pizzuti M
    Front Immunol; 2022; 13():892331. PubMed ID: 36003404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity.
    Kara Z; Akçin R; Demir AN; Dinç HÖ; Taşkın HE; Kocazeybek B; Yumuk VD
    Obes Surg; 2022 Sep; 32(9):2987-2993. PubMed ID: 35802279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Humoral Response After a Second Dose of SARS-CoV-2 mRNA Vaccine in Japanese Kidney Transplant Recipients.
    Ohki Y; Kawabe M; Yamamoto I; Katsumata H; Nakada Y; Kobayashi A; Urabe F; Miki J; Yamada H; Kimura T; Matsuo N; Tanno Y; Horino T; Ohkido I; Yamamoto H; Yokoo T
    Front Microbiol; 2022; 13():922042. PubMed ID: 35756063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
    Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
    Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients.
    Hirai K; Shimotashiro M; Sonoda T; Okumura T; Ookawara S; Morishita Y
    Clin Exp Nephrol; 2022 Sep; 26(9):925-932. PubMed ID: 35426594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.
    Matsuura T; Fukushima W; Nakagama Y; Kido Y; Kase T; Kondo K; Kaku N; Matsumoto K; Suita A; Komiya E; Mukai E; Nitahara Y; Konishi A; Kasamatsu A; Nakagami-Yamaguchi E; Ohfuji S; Kaneko Y; Kaneko A; Kakeya H; Hirota Y
    Vaccine; 2022 Sep; 40(38):5631-5640. PubMed ID: 36028457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.